In vitro anti-cancer effects of the actin-binding natural compound rhizopodin

Area of Science:

• Natural product chemistry
• Cell biology
• Cancer pharmacology

Background:

• Microtubule-targeting agents like Vinca-alkaloids and taxanes are established cancer therapies.
• Pharmacological understanding of actin-binding drugs is limited, hindering their clinical application.
• Rhizopodin is a natural compound with known antibacterial and cytotoxic effects, impacting the actin cytoskeleton at nanomolar concentrations.

Purpose of the Study:

• To investigate the anti-cancer potential of rhizopodin.
• To characterize the cellular and pharmacological effects of rhizopodin on cancer cells.
• To explore rhizopodin's mechanism of action, particularly its interaction with the actin cytoskeleton.

Main Methods:

• Actin-pyrene assay and immunostaining to visualize effects on the actin cytoskeleton.
• Cell proliferation assays.
• Propidium iodide exclusion and Western blot to assess cell death induction.
• Impedance measurements using the xCELLigence device to analyze cell migration.
• Experiments conducted on MDA-MB-231 breast and T24 bladder cancer cell lines.

Main Results:

• Rhizopodin demonstrated significant effects on the actin cytoskeleton in cancer cells.
• The compound inhibited proliferation and induced cell death in both MDA-MB-231 and T24 cell lines at nanomolar concentrations.
• PARP cleavage indicated caspase-dependent apoptosis induction.
• Rhizopodin potently inhibited cancer cell migration at subtoxic doses, suggesting specific signaling pathways are involved.

Conclusions:

• Rhizopodin is an actin-binding natural compound with potent anti-cancer properties.
• It effectively inhibits cancer cell proliferation, induces cell death, and reduces cell migration.
• These findings establish a foundation for further research into rhizopodin as a potential antitumoral agent.